Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-23-025286
Date:2023-04-19
Issuer: TRACON PHARMACEUTICALS, INC. (TCON)
Original Submission Date:

Reporting Person:

PELLETIER SAUNDRA L
C/O TRACON PHARMACEUTICALS, INC.
4350 LA JOLLA VILLAGE DRIVE, SUITE 800 SAN DIEGO, CA 92122

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
DIRECTOR STOCK OPTION (RIGHT TO BUY) 1.82 2023-04-19 deemed execution date A 18,000 (a) 2033-04-18 common stock 18,000 $1.82 18,000 direct
Footnotes
IDfootnote
f1 the shares subject to the option shall vest and become exercisable on the earlier of the first anniversary of the grant date set forth in column 3 above or the date of the next annual meeting of the company's stockholders, subject to the optionee's continuous service (as defined in the company's 2015 equityincentive plan (the "plan")) and accelerated on the closing of a change of control (as defined in the plan).
WhaleWisdom Logo

Elevate your investments